Abbott, a global healthcare leader, has recently announced a groundbreaking partnership with Medtronic to integrate continuous glucose monitoring (CGM) sensors based on Abbott’s FreeStyle Libre technology with Medtronic’s insulin delivery systems. This unique collaboration will offer more choices to individuals worldwide who can benefit from the connectivity provided by Libre technology.
By combining Abbott’s CGM sensor with Medtronic’s automated insulin delivery (AID) algorithms, the integrated system will allow for automatic adjustments of insulin to maintain glucose levels within the target range. This development is particularly beneficial for individuals with both Type 1 and Type 2 diabetes who require intensive insulin therapy.
Jared Watkin, executive vice president of Abbott’s diabetes care business, emphasized the importance of this partnership, stating that Libre technology has set the standard for accurate and reliable continuous glucose monitoring. By connecting this CGM technology with Medtronic’s insulin delivery systems, individuals can now focus less on managing their diabetes and more on living their lives to the fullest.
Que Dallara, executive vice president and president of Medtronic Diabetes, expressed the company’s commitment to simplifying diabetes management and making the transition to automated technology seamless for those seeking to enhance their diabetes care.
This collaboration with Medtronic is part of Abbott’s ongoing efforts to improve and streamline diabetes care, providing individuals with a variety of options for insulin administration. Abbott’s Libre portfolio, which is used by over 6 million people in more than 60 countries, has been shown to help individuals improve glucose control, lower HbA1c levels, reduce diabetes-related hospital admissions, and enhance their quality of life.
Abbott’s continuous glucose monitoring technology has received partial or full reimbursement in over 40 countries, highlighting its global impact on diabetes management. This partnership with Medtronic marks a significant milestone in advancing diabetes care and empowering individuals to take control of their health.
In addition to this partnership, Abbott continues to collaborate with other insulin delivery companies to integrate its Libre technology with various automated insulin delivery offerings. By expanding access to advanced insulin delivery systems and CGM technology, Abbott aims to provide individuals with the tools they need to effectively manage their diabetes and improve their overall well-being.
As the world’s leading continuous glucose monitoring technology, Abbott’s Libre systems have proven to be instrumental in transforming diabetes care and helping individuals lead healthier, more fulfilling lives. With a strong focus on innovation and partnership, Abbott remains dedicated to enhancing the quality of life for people living with diabetes worldwide.